Nefopam Chlorhydrate Eg Labo (Nefopam Hydrochloride)

Nefopam Hydrochloride, the active ingredient in Nefopam Chlorhydrate Eg Labo, is a non‑opioid analgesic presented as a sterile injectable for intramuscular and intravenous use. It is employed to manage moderate acute pain, including postoperative pain, in adult patients.

GNH USA supplies Nefopam Chlorhydrate Eg Labo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nefopam Hydrochloride is used to treat pain conditions that involve central pain pathways.

- Moderate acute pain: provides analgesia for sudden, short‑term pain episodes such as injury or trauma. - Post‑operative pain: helps control pain following surgical procedures. - Pain after major trauma: reduces discomfort associated with severe tissue injury.

Nefopam may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Sweating: increased perspiration without exertion. - Dry mouth: reduced salivation. - Dizziness: light‑headed sensation. - Tachycardia: faster than normal heart rate. - Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects: - Seizures: convulsive episodes, especially in predisposed individuals. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm. - Hepatic dysfunction: abnormal liver enzyme elevations. - Neuropsychiatric effects: agitation or confusion.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Cardiovascular assessment: check blood pressure and heart rate before use. - Seizure risk: avoid in patients with a history of epilepsy. - Hepatic/renal function: adjust use if liver or kidney impairment is present. - Glaucoma caution: monitor intra‑ocular pressure in susceptible patients. - Discontinuation: taper gradually to prevent withdrawal phenomena. - Store below 25°C: keep in the original container, protect from light and moisture.

Nefopam can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs): increased serotonin toxicity. - Tricyclic antidepressants: heightened seizure risk. - Antihypertensive agents: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., fluoxetine): may raise nefopam plasma levels. - CYP450 inducers (e.g., carbamazepine): may reduce efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined gastrointestinal irritation. - Anticholinergic drugs: may exacerbate dry mouth. - Diuretics: potential electrolyte disturbances.